

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**ASTRAZENECA PHARMACEUTICALS LP**

2. Address:

1800 CONCORD PIKE P.O. BOX 15437, WILMINGTON, DE 19850-5437

3. Principal place of business (if different from line 2):

Country: City: State/Zip(or Country):

4. Contact Name: THOMAS F. FELTON

Telephone: 302-885-4873

E-mail (optional): thomas.felton@astrazeneca.com

Senate ID #: 54073-12

House ID #: 34975000

7. Client Name:  Self

## TYPE OF REPORT

8. Year 2006 Midyear (January 1 - June 30):  **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report:  => Termination Date: 11. No Lobbying Activity:

## INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more:  => Income (nearest \$20,000): \_\_\_\_\_

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more:  => Expenses (nearest \$20,000): 1,460,000.00

### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only  
 **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  
 **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: ASTRAZENECA PHARMACEUTICALS LP Client Name: Self

**LOBBYING ACTIVITY.**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

H.R. 1, Deficit Reduction Act

17. House(s) of Congress and Federal agencies contacted:

US HOUSE OF REPRESENTATIVES  
US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ESPOSITO, ANNE  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ASTRAZENECA PHARMACEUTICALS LP Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

S. 2300, Lower Priced Drug Act - with regard to intellectual property issues. H.R. 2795, Patent Reform Act of 2005 - with regard to intellectual property issues.

17. House(s) of Congress and Federal agencies contacted:

US HOUSE OF REPRESENTATIVES  
US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUCKLEY, RICHARD  
Covered Official Position (if applicable):  
Name: ROSSIN, BRADLEY  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ASTRAZENECA PHARMACEUTICALS LP Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CSP (one per page)

16. Specific lobbying issues:

H.R. 5441, Homeland Security Appropriations H.R. 5384, Agricultural Appropriations S. 334, The Pharmaceutical Market Access and Drug Safety Act of 2005 S. 109, The Pharmaceutical Market Access Act of 2005 S. 184, Safe Import Act of 2005 All with regard to importation issues.

17. House(s) of Congress and Federal agencies contacted:

US HOUSE OF REPRESENTATIVES  
US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUCKLEY, RICHARD  
Covered Official Position (if applicable):  
Name: POMFRET, JACQUI  
Covered Official Position (if applicable):  
Name: ROSSIN, BRADLEY  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ASTRAZENECA PHARMACEUTICALS LP Client Name: Self

**LOBBYING ACTIVITY.**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: DEF (one per page)

16. Specific lobbying issues:

S. 2766 and H.R. 5122, Defense Authorization Bill - with regard to price control issues.

17. House(s) of Congress and Federal agencies contacted:

US HOUSE OF REPRESENTATIVES  
US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUCKLEY, RICHARD  
Covered Official Position (if applicable):  
Name: ROSSIN, BRADLEY  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ASTRAZENECA PHARMACEUTICALS LP Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

H.R. 3561, Healthcare Equality and Accountability Act - with regard to minority health issues.

17. House(s) of Congress and Federal agencies contacted:

US HOUSE OF REPRESENTATIVES  
US SENATE

US HOUSE OF REPRESENTATIVES  
US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUCKLEY, RICHARD  
Covered Official Position (if applicable):  
Name: ROSSIN, BRADLEY  
Covered Official Position (if applicable):  
Name: STEWART, JENNIFER  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ASTRAZENECA PHARMACEUTICALS LP Client Name: Self

**LOBBYING ACTIVITY.**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

H.R. 898 and S. 106 . Stroke Treatment and Ongoing Prevention (STOP) Act - with regard to stroke issues.

17. House(s) of Congress and Federal agencies contacted:

US HOUSE OF REPRESENTATIVES  
US SENATE

US HOUSE OF REPRESENTATIVES  
US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUCKLEY, RICHARD  
Covered Official Position (if applicable):  
Name: ROSSIN, BRADLEY  
Covered Official Position (if applicable):  
Name: STEWART, JENNIFER  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ASTRAZENECA PHARMACEUTICALS LP Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

Medicare and Medicaid issues with focus on reimbursement.

17. House(s) of Congress and Federal agencies contacted:

Centers for Medicare & Medicaid Services

Health & Human Services

US HOUSE OF REPRESENTATIVES

US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: DAVIS, CHESTER 'CHIP'

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**



Registrant Name: ASTRAZENECA PHARMACEUTICALS LP Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TRD (one per page)

16. Specific lobbying issues:

H.R. 5337, Foreign Investment and National Security Act - with regard to trade issues. S.3549, Foreign Investment and National Security Act - with regard to trade issues.

17. House(s) of Congress and Federal agencies contacted:

US HOUSE OF REPRESENTATIVES  
US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: STEWART, JENNIFER  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Aug 14, 2006

Printed Name and Title: Thomas F. Felton, Counsel -

Registrant Name: ASTRAZENECA PHARMACEUTICALS LP Client Name: Self

### Information Update Page:

Complete **ONLY** where registration information has changed.

**21. Client new principal place of business (if different from line 20):**

Country: USA

### LOBBYIST UPDATE

**23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client**

Name: Deschenes, Elise

### ISSUE UPDATE

**24. General lobbying issues previously reported that NO LONGER pertain**

### AFFILIATED ORGANIZATIONS

**25. Add the following organization(s)**

**26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client**

### FOREIGN ENTITIES

**27. Add the following foreign entities**

**28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization**

Signature: ON FILE Date: Aug 14, 2006

Printed Name and Title: THOMAS F. FELTON, COUNSEL -